Images and logos
Interim Report for Kancera AB (publ) Q3 2012
Kancera strengthens the evidence that pancreatic cancer is dependent on ROR
Kancera reports inhibitory effects on pancreatic cancer in animal studies
Intellect Neurosciences and iNovacia Enter into a Research Service Agreement
Interim Report for Kancera AB (publ) Q2 2012
Kancera strengthens patent rights related to ROR antibody therapy
Kancera to present at the 2012 BIO International Convention
Professor Carl-Henrik Heldin strengthens the Board of Kancera
Interim Report for Kancera AB (publ) Q1 2012
Kancera´s ROR inhibitors are active against Fludarabine resistant leukemia
A new diagnostic tool increases the value of Kancera´s ROR technology
Data indicate broad utility of Kancera’s PFKFB3 inhibitors.
Kancera presents at Boston seminar April 27th, 2012.
Kanceras ROR project has been selected for presentation at the ASCO annual meeting in Chicago.
Kancera’s ROR inhibitors show superior efficacy in 3D pancreatic tumor model.
Full Year Report 2011 for Kancera AB (publ)
Kancera’s ROR-inhibitor provides higher specificity than competing products
Kancera file patents for ROR inhibitors against cancer
Kanceras strategy is given attention when global expertise in cancer gathers in Washington DC
iNovacia announces collaboration with Agios Pharmaceuticals
Recieve our releases/reports by email when they are distributed.
Copyright 2010 KANCERA AB, KAROLINSKA INSTITUTET SCIENCE PARK, BANVAKTSVÄGEN 22, 171 48 SOLNA. TEL: +46 (0)850 12 60 80